Burnham ambition

Fifth member of The Smiths attempts to write a compelling chorus

So, Andy Burnham’s NHS – what does this Prime Minister mean for pharma?

With prevention, integration and devolution at the heart of his political philosophy, Andy Burnham brings an unusually developed vision of healthcare to Downing Street. But will his brand of ‘business-friendly socialism’ deliver for the pharmaceutical industry?

In June 2009, I found myself in a press huddle with Andy Burnham, newly installed as Health Secretary in Gordon Brown’s government. He looked about 16, had been in the job for barely a week, and after I got over quite how big his eyes were, I asked him what his overriding priority would be. His answer was immediate: prevention.

Seventeen years later, Burnham is Prime Minister, and remarkably little has changed. Prevention has become the organising principle of his political philosophy, extending beyond healthcare into housing, education, employment and welfare.

At my training company Life Science Access Academy, our clients are asking us how to prepare for the future. Well, it may well involve a thorough understanding of this word, prevention, in healthcare. For only prevention, in its widest sense, will ultimately reduce the inexorable demand on the NHS.
For Britain’s pharmaceutical industry, understanding this philosophy may be the key to understanding the next three years of NHS policy – and potentially considerably longer.

The Manchester model

But first, a little more about the man. Burnham is unusual among prime ministers in having both run the Department of Health and spent nearly a decade developing his own approach to public service reform.

As Mayor of Greater Manchester between 2017 and 2026, he championed ‘Manchesterism’: a blend of devolution, public service integration, economic development and active government.

Its central proposition is that Whitehall’s departmental boundaries frequently obstruct progress. Poor housing produces ill health. Ill health reduces employment and productivity. Inadequate social care causes hospital admissions and delayed discharges. These interconnected problems require coordinated solutions.

Greater Manchester’s experiment in health and social care devolution enabled some of these ideas to be tested. Its achievements have been mixed but encouraging, with research identifying improvements in life expectancy, well-being and some indicators of health inequality, although obesity and emergency care pressures remain stubborn.

Burnham’s ambition is now to apply this approach nationally.

Prevention, in this worldview, extends beyond vaccinations, screening and healthy lifestyles. It means intervening earlier across health, care and social policy – including with medicines, digital and device interventions – rather than paying considerably more to address the consequences later.

This is entirely consistent with the three shifts underpinning the existing 10 Year Health Plan: hospital to community, analogue to digital, and sickness to prevention. Burnham has inherited a programme that, philosophically at least, he might have written himself.

Friend or foe of pharma?

The pharmaceutical industry might reasonably wonder whether a politician associated with public ownership, state intervention and democratic socialism will prove sympathetic to its commercial interests.

The evidence suggests a nuanced answer.

Burnham has characterised his economic philosophy as ‘business-friendly socialism’, and Greater Manchester’s development depended heavily upon partnerships with private investors.

Life sciences were among its important growth sectors, with the city region developing a substantial innovation ecosystem connecting universities, NHS organisations, technology companies and pharmaceutical manufacturers.

Health Innovation Manchester, established in 2017, embodies the collaboration Burnham favours: connecting industry and research with local health service needs.

He is neither instinctively hostile to private enterprise nor an enthusiast for outsourcing public services. Burnham appears comfortable with businesses generating profits through innovation and investment, while remaining sceptical about private interests extracting value from essential public services.

For pharma, that suggests opportunity accompanied by expectations.

Companies demonstrating how their medicines prevent deterioration, reduce hospitalisation, support earlier diagnosis or keep people economically active will find themselves speaking Burnham’s language.

The proposition that a treatment deserves NHS funding simply because it is innovative may prove less persuasive.

And prevention should not be confused with cheap interventions. Effective medicines for obesity, cardiovascular disease, diabetes and other chronic conditions could become central to his agenda, particularly where benefits extend beyond conventional clinical endpoints.

The commercial realities

There is, however, considerable difference between being pro-life sciences and pro-pharmaceutical pricing.

The UK-US pharmaceuticals agreement has already committed Britain to higher spending on innovative medicines, changes to NICE’s cost-effectiveness thresholds and a more favourable commercial environment.

The successor to the current voluntary pricing agreement, due in January 2029, will test Burnham’s relationship with industry.

His government must reconcile commitments to pharmaceutical investment with NHS financial constraints. Manufacturers seeking improved returns will face competing demands from social care, community services, workforce investment and hospital recovery.

There is also tension between national efforts to accelerate medicines access and Burnham’s enthusiasm for devolution.

The developing Single National Formulary, for example, seeks to reduce unwarranted geographical prescribing variation. But a more locally empowered NHS raises questions about who controls implementation, prescribing priorities and resources.

Burnham must balance local autonomy with national consistency. Ultimately, the industry’s most productive argument may be economic: that effective medicines adoption contributes to a healthier workforce, reduced demand for expensive services, and improved productivity.

Why Yvette Cooper?

Burnham’s appointment of Yvette Cooper as Health and Social Care Secretary was revealing.

Cooper – your classic ‘safe pair of hands’ – is among Labour’s most experienced political operators, having held senior government positions including at the Treasury, Home Office and Foreign Office. She also served as a junior health minister between 1999 and 2002, contributing to the first NHS Cancer Plan.

Her appointment provides political authority to a portfolio undergoing major structural change.

It suggests Burnham has little interest in making healthcare a one-man operation.

Cooper’s unlikely to approach the brief as a campaigning outsider seeking wholesale transformation. She is more plausibly a disciplined, detail-oriented administrator focused on performance, accountability and implementation.

Her initial priorities reinforce that impression: maternity safety, social care, mental health and operational pressures.

Above all, Cooper’s appointment appears designed to give social care the prominence Burnham believes it has lacked.

She has the experience to challenge the Treasury, coordinate colleagues and manage conflicts accompanying reform.

For pharma, she may prove a demanding rather than ideological interlocutor: interested in evidence, deliverability and demonstrable benefits, but operating within a government whose ambitions extend beyond medicines policy.

The big-ticket agenda

The most consequential development may be Burnham’s determination to confront the long-standing failure to reform social care.

His proposed National Care Service, announced in September, would ultimately introduce free personal care for older people, supported by changes to the state pension settlement. Baroness Casey’s commission is expected to report in summer 2027, with implementation envisaged during the next Parliament.

This is politically ambitious and financially hazardous, but consistent with Burnham’s belief that health and social care cannot operate separately.
Meanwhile, the Health Bill progressing through Parliament will reshape NHS governance.

Its central measure is the abolition of NHS England, transferring responsibilities to DHSC and integrated care boards. Other provisions include enabling a single patient record, changing patient safety arrangements and giving local NHS organisations greater flexibility.

The legislation also envisages closer relationships between ICBs and elected regional leadership, including mayoral representation.

This expresses Burnham’s belief that democratic accountability and devolution should play greater roles in public services.

Yet the Bill highlights a contradiction. Abolishing NHS England concentrates authority in ministers’ hands, potentially increasing central control while government promises local autonomy.

Resolving that tension will be critical.

Alongside structural reform, Burnham must sustain improvements in waiting times, cancer services, urgent care, mental health and patient safety while delivering neighbourhood health services.

The pitfalls

Burnham’s greatest difficulty may be that his preferred reforms require investment now to produce savings much later.

Prevention is attractive but financially awkward. Funding community services, early intervention and social care while maintaining hospital capacity creates substantial transitional costs.

There is no guarantee reduced acute demand will materialise quickly enough to release resources.

Devolution brings complications too. Greater Manchester benefited from distinctive political leadership, institutional relationships and civic identity. Reproducing its model across England, where local government capacity and NHS relationships differ, will not be straightforward.

And NHS structural change has an unfortunate tendency to consume the managerial attention required for actual improvement.

Abolishing NHS England is particularly formidable, with responsibilities, staff and accountability arrangements requiring reorganisation.

These obstacles could frustrate even a prime minister deeply committed to reform.

The 2029 question

Yet Burnham has one significant advantage: an increasingly credible prospect of winning the next general election.

Recent polling suggests Labour has recovered ground under his leadership, with Burnham retaining stronger personal ratings than his principal opponents. Victory in 2029 is far from guaranteed, but increasingly plausible.

A renewed mandate would radically improve the prospects for the 10 Year Health Plan.

Without one, Burnham may spend his premiership laying foundations that a successor could abandon. With another parliamentary term, he would have time to implement social care reform, develop neighbourhood health services and demonstrate whether prevention genuinely reduces NHS demand.

That would give Pharma a coherent policy direction stretching into the 2030s.

But it would demand a different relationship with government: less narrowly focused on individual product pricing and reimbursement, and more concerned with contributions to population health, prevention, service transformation and economic growth.

I remember that young Health Secretary’s answer in 2009 because it was unequivocal. Prevention was a priority then, and remains so today. The difference is that Andy Burnham now has an opportunity to make it the organising principle in healthcare.

Whether the NHS – and the pharmaceutical industry – can adapt to that ambition may define his premiership.